{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:21:48Z","timestamp":1783959708771,"version":"3.55.0"},"reference-count":47,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["MDM Policy &amp; Practice"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative disease characterized by motor and nonmotor symptoms that worsen over time. In some cases, an advanced treatment may be needed. The use of levodopa-carbidopa intestinal gel (LCIG) is one of these options. However, deciding whether to receive it can be difficult. A patient decision aid (PDA), a tool designed to inform about treatment options, can help and promote patients\u2019 participation in decision making.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>This study was conducted to develop a PDA on LCIG and assess its acceptability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>\n              The International Patient Decision Aid Standards framework was used to develop the PDA. An advisory committee (\n              <jats:italic>n<\/jats:italic>\n              = 5) gave feedback on the PDA prototype. Acceptability was evaluated using a cross-sectional descriptive design. A convenience sample of 36 participants (including persons with PD receiving and not receiving LCIG, caregivers, and health care professionals) was used. Acceptability data, sociodemographics, and health literacy were collected using questionnaires and a focus group.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              Sample characteristics were a mean age of 64.4 y (\n              <jats:italic>s<\/jats:italic>\n              = 14 y), university level of education (46.7%), and duration of illness of less than 10\u2009y (80%). The health literacy score was judged as very good (\n              <jats:inline-formula>\n                <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" display=\"inline\" overflow=\"scroll\">\n                  <mml:mrow>\n                    <mml:mover>\n                      <mml:mrow>\n                        <mml:mi>x<\/mml:mi>\n                      <\/mml:mrow>\n                      <mml:mo>\u00af<\/mml:mo>\n                    <\/mml:mover>\n                  <\/mml:mrow>\n                <\/mml:math>\n              <\/jats:inline-formula>\n              = 55.2\/70,\n              <jats:italic>s<\/jats:italic>\n              = 7.3). Qualitative data analysis allowed for final adjustments to the published PDA version.\n              <jats:bold>Conclusions.<\/jats:bold>\n              This study is the first to report the development of a PDA on LCIG and its acceptability testing. Participants found the PDA to be useful and would recommend it. All health care professionals indicated they intended to use it in their practice. More research will be needed to evaluate the PDA\u2019s implementation and its effects on users.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Highlights<\/jats:title>\n            <jats:list list-type=\"bullet\">\n              <jats:list-item>\n                <jats:p>Deciding whether to opt for an advanced Parkinson\u2019s disease treatment such as levodopa-carbidopa intestinal gel can be challenging for many patients.<\/jats:p>\n              <\/jats:list-item>\n              <jats:list-item>\n                <jats:p>A patient decision aid on levodopa-carbidopa intestinal gel for Parkinson\u2019s disease persons, caregivers, and health care professionals was developed to support a decision-making process.<\/jats:p>\n              <\/jats:list-item>\n              <jats:list-item>\n                <jats:p>This article summarizes the steps used for its development and its acceptability testing.<\/jats:p>\n              <\/jats:list-item>\n            <\/jats:list>\n          <\/jats:sec>","DOI":"10.1177\/23814683251364883","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:48:55Z","timestamp":1757504935000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and Acceptability Testing of a Patient Decision Aid on Levodopa Intestinal Gel for Parkinson Disease"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-6089","authenticated-orcid":false,"given":"Andreanne","family":"Tanguay","sequence":"first","affiliation":[{"name":"School of Nursing, Faculty of Medicine and Health sciences, University of Sherbrooke, Sherbrooke, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-612X","authenticated-orcid":false,"given":"Caroline","family":"Cayer","sequence":"additional","affiliation":[{"name":"CIUSSS de l\u2019Estrie-CHUS, Centre de Recherche du CHUS - Neurology Service, Sherbrooke, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7409-9993","authenticated-orcid":false,"given":"Isabelle","family":"Beaulieu-Boire","sequence":"additional","affiliation":[{"name":"CIUSSS de l\u2019Estrie CHUS \u2013 Fleurimont Hospital, Sherbrooke, QC, Canada"},{"name":"Department of Neurology, Faculty of Medicine and Health sciences, University of Sherbrooke, Sherbrooke, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Parkinson Canada. Canadian guideline for Parkinson disease. What is Parkinson\u2019s?2023. Available from: http:\/\/www.parkinsonclinicalguidelines.ca\/parkinsons-disease\/?_ga=2.181468005.313912238.1647958810-700432351.1647958810"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00218-x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(18)30295-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00693"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3654"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.181504"},{"issue":"604","key":"e_1_3_3_9_2","article-title":"Maladie de Parkinson au stade avanc\u00e9: indication aux traitements complexes","volume":"14","author":"Bereau M","year":"2018","unstructured":"Bereau M, Tomkova E, Zacharia A, et al. Maladie de Parkinson au stade avanc\u00e9: indication aux traitements complexes. RevMed. 2018;14(604):875-8.","journal-title":"RevMed"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02668-9"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2020.100038"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00896"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S27180"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010532"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2017-006986"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001431.pub5"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2017-006985"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-13-S2-S2"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38926.629329.AE"},{"key":"e_1_3_3_20_2","unstructured":"Universit\u00e9 Laval. Conception d\u2019outils d\u2019aide \u00e0 la prise de d\u00e9cision partag\u00e9e. 2019. Available from: https:\/\/www.boitedecision.ulaval.ca\/formations\/conception-outils\/"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X20984134"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2196\/17482"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-160816"},{"key":"e_1_3_3_24_2","unstructured":"Abbvie Corporation. Canadian Drug Expert Committee recommendation. CADTH common drug review patient input for Duodopa; 2018. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/relatedinfo\/SR0557_Duodopa_PI_Submissions.pdf"},{"issue":"8","key":"e_1_3_3_25_2","article-title":"Are you SURE? Assessing patient decisional conflict with a 4-item screening test","volume":"56","author":"L\u00e9gar\u00e9 F","year":"2010","unstructured":"L\u00e9gar\u00e9 F, Kearing S, Clay K, et al. Are you SURE? Assessing patient decisional conflict with a 4-item screening test. Can Fam Physician. 2010;56(8):e308\u201314.","journal-title":"Can Fam Physician"},{"key":"e_1_3_3_26_2","unstructured":"Ottawa Hospital Research Institute. Evaluation measures. Patient decision aids. 2021. Available from: https:\/\/decisionaid.ohri.ca\/francais\/meseval.html"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-018-0286-4"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2031-8"},{"key":"e_1_3_3_29_2","unstructured":"Universit\u00e9 Laval. \u00c9valuer l\u2019implantation d\u2019un outil d\u2019aide \u00e0 la d\u00e9cision. Conception d\u2019outils d\u2019aide \u00e0 la prise de d\u00e9cision partag\u00e9e; 2022. Available from: https:\/\/www.boitedecision.ulaval.ca\/fr\/formations\/conception-outils\/section-4-module-b\/"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1382-7"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2014.07.690"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000341"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wombi.2020.12.007"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3758\/BF03195514"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X211011101"},{"key":"e_1_3_3_36_2","unstructured":"O\u2019Connor A Elwyn G Barratt A et al. IPDAS\u2014criteria for judging the quality of patient decision aids. 2005. Available from: http:\/\/ipdas.ohri.ca\/IPDAS_checklist.pdf"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-80"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-018-0027-8"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/heapro\/15.3.259"},{"key":"e_1_3_3_40_2","unstructured":"O\u2019Connor A Jacobsen M. Workbook on Developing and Evaluating Patient Decision Aids. 2003. Available from: https:\/\/decisionaid.ohri.ca\/docs\/develop\/develop_da.pdf"},{"key":"e_1_3_3_41_2","volume-title":"L\u2019entretien de recherche qualitatif: Th\u00e9orie et pratique","author":"Boutin G.","year":"2003","unstructured":"Boutin G. L\u2019entretien de recherche qualitatif: Th\u00e9orie et pratique. Quebec: Presses de l\u2019Universit\u00e9 du Qu\u00e9bec; 2003."},{"key":"e_1_3_3_42_2","unstructured":"O\u2019Connor A Cranney A. User Manual\u2014Acceptability. Institut de recherche de l\u2019H\u00f4pital d\u2019Ottawa. 2002. Available from: https:\/\/decisionaid.ohri.ca\/eval_accept.html"},{"key":"e_1_3_3_43_2","unstructured":"Schippers B. Implementation of a shared-decision making intervention in advanced Parkinson\u2019s disease\u2014a multi-center mixed methods feasibility study [master\u2019s thesis]. University of Twente; 2020. Available from: http:\/\/essay.utwente.nl\/84098\/"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.2.318"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2014.10.006"},{"key":"e_1_3_3_46_2","unstructured":"Statistics Canada. Non-probability sampling; 2021. Available from: https:\/\/www150.statcan.gc.ca\/n1\/edu\/power-pouvoir\/ch13\/nonprob\/5214898-eng.htm"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1353\/book80985"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-019-0098-0"}],"container-title":["MDM Policy &amp; Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23814683251364883","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23814683251364883","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23814683251364883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T13:22:19Z","timestamp":1757683339000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23814683251364883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/23814683251364883"],"URL":"https:\/\/doi.org\/10.1177\/23814683251364883","relation":{},"ISSN":["2381-4683","2381-4683"],"issn-type":[{"value":"2381-4683","type":"print"},{"value":"2381-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"23814683251364883"}}